Cantor Fitzgerald Reports Initiation of Aduro Biotech (ADRO) with $15 Target; Shorts at HOYA ORDINARY SHARES JAPAN (HOCPF) Raised By 31.8%

February 22, 2018 - By Nellie Frank

HOYA CORP ORDINARY SHARES JAPAN (OTCMKTS:HOCPF) had an increase of 31.8% in short interest. HOCPF’s SI was 195,200 shares in February as released by FINRA. Its up 31.8% from 148,100 shares previously. With 1,900 avg volume, 103 days are for HOYA CORP ORDINARY SHARES JAPAN (OTCMKTS:HOCPF)’s short sellers to cover HOCPF’s short positions. The SI to HOYA CORP ORDINARY SHARES JAPAN’s float is 0.05%. It closed at $50.33 lastly. It is down 0.00% since February 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 9 analysts covering Aduro Biotech (NASDAQ:ADRO), 7 have Buy rating, 1 Sell and 1 Hold. Therefore 78% are positive. Aduro Biotech has $68 highest and $9.5 lowest target. $27.69’s average target is 334.01% above currents $6.38 stock price. Aduro Biotech had 19 analyst reports since August 19, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, December 1 by Oppenheimer. The stock of Aduro BioTech, Inc. (NASDAQ:ADRO) earned “Buy” rating by H.C. Wainwright on Thursday, August 3. The rating was maintained by Roth Capital on Tuesday, November 24 with “Buy”. The rating was upgraded by Zacks on Thursday, September 3 to “Hold”. Cowen & Co initiated the stock with “Buy” rating in Tuesday, July 18 report. H.C. Wainwright maintained Aduro BioTech, Inc. (NASDAQ:ADRO) rating on Wednesday, November 1. H.C. Wainwright has “Buy” rating and $18.0 target. The stock has “Buy” rating by Oppenheimer on Monday, October 30. Leerink Swann initiated the shares of ADRO in report on Wednesday, August 19 with “” rating. The firm has “Buy” rating given on Thursday, August 27 by Roth Capital. As per Tuesday, March 7, the company rating was maintained by Roth Capital.

Analysts await Aduro BioTech, Inc. (NASDAQ:ADRO) to report earnings on March, 7. They expect $-0.36 EPS, up 18.18% or $0.08 from last year’s $-0.44 per share. After $-0.33 actual EPS reported by Aduro BioTech, Inc. for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. The company has market cap of $492.81 million. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. It currently has negative earnings. The firm is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts